S-ClassAbout S-Class
B
BWXTAI Stock Diagnostic Report
BWXT targets $4.70-$4.80 EPS and raises 2026 free cash flow outlook to $345M-$360M amid medical sale
BWX Technologies provided guidance for earnings per share (EPS) for 2026 and raised its free cash flow outlook, demonstrating strong performance.
View Source Article ↗AI CATALYST SCORE85 / 100Score computed by Sentinel V12
REFERENCE PRICE$173.79Reference entry price at analysis time
01
MARKET SNAPSHOT
Key Indicators at a Glance
Major Support157.10
Near-Term Resistance195.32
02
FUNDAMENTALS
Financial & Fundamental Analysis
BWXT presented its Q2 2026 earnings report, providing EPS guidance of $4.70-$4.80 and raising its free cash flow (FCF) outlook to $345M-$360M, demonstrating solid financial performance and operational efficiency.
03
TECHNICAL VIEW
Technical Position & Response Criteria
The current price of $173.79 is positioned between the 20-day resistance level ($195.32) and the support level ($157.10), and since it is in a period of undefined moving average arrangement, a split approach near the support level is advantageous.
Support157.10
Resistance195.32
04
CATALYST & STRATEGY
Catalyst Analysis & Forward Strategy
The ongoing momentum in the commercial nuclear sector, coupled with the push to divest the medical sales division, is providing clear visibility into performance improvements that the company can directly control.
05
PROOF OF WORK
Analysis Point vs. Subsequent Price Action
INITIAL · At Analysis (2026-08-04)
FINAL · Current/Verified
Renders the actual stored OHLC data directly in your browser.